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AJH 2004; 17:817–822Background: The possibility that specific antihyper-
tensive treatments may prevent the occurrence of stroke
more effectively than other treatments remains unproved.
We undertook a meta-analysis to assess whether calcium
channel blockers (CCBs) are associated with a lesser risk
of stroke as compared with other antihypertensive drugs.
Methods: Through Medline we identified 13 major
studies conducted in hypertensive subjects for a total of
103,793 subjects. Overall, there were 4040 incident cases
of stroke, 1789 among 43,053 subjects randomized to
CCBs and 2251 among 60,740 subjects randomized to
different antihypertensive drugs.
Results: Considering all 13 trials, a pooled reduction in
the risk of stroke was observed among subjects allocated
to CCBs (odds ratio 0.90, 95% confidence interval [95%
CI] 0.84–0.96; P  .002). The risk of stroke was signif-
icantly lower among subjects allocated to dihydropyridine
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Published by Elsevier Inc.CCBs than among those randomized to alternative drugs
(odds ratio 0.90, 95% CI 0.84–0.97; P  .006), whereas
the effect of non-dihydropyridine CCBs did not achieve
significance (odds ratio 0.92, 95% CI 0.81–1.04). In a
meta-regression analysis of these trials, the protection
from stroke conferred by CCBs appeared unrelated to the
degree of systolic blood pressure reduction.
Conclusions: These findings suggest that CCBs de-
crease the risk of stroke more effectively than other treat-
ments in patients with essential hypertension and that such an
effect might not be completely explained by a better antihy-
pertensive response. Calcium channel blockers should be
considered in hypertensive subjects at increased risk of
stroke. Am J Hypertens 2004;17:817–822 © 2004 Amer-
ican Journal of Hypertension, Ltd.
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blockers, therapy, prevention.H ypertension is a potent risk factor for fatal andnonfatal strokes.1–4 In a pooled analysis of 61prospective studies including about one million
of individuals, the risk of stroke increased progressively
with blood pressure (BP) from values as low as 115/75
mm Hg without any evidence of a threshold.5 Such rela-
tion was consistent at all ages.5 Blood pressure lowering
strongly reduces the risk of stroke,6–8 but the possibility
that specific drugs may prevail over others for protection
from stroke remains unsettled. In a meta-analysis of nine
trials, calcium channel blockers (CCBs) were associated
with a nonsignificant 10% lesser risk of stroke when
compared with different antihypertensive drugs.9 In an-
other meta-analysis, CCBs provided a 13.5% reduction in
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-blockers.7 In the second cycle of analyses issued by the
Blood Pressure Lowering Treatment Trials Collaboration
(BPLTTC), there was a trend toward a greater reduction in
the risk of stroke with regimens based on CCBs than with
regimens based on angiotensin-converting enzyme inhib-
itors (ACEIs) (12% reduction) or diuretics and/or -block-
ers (7% reduction), but none of these differences achieved
statistical significance.8
From a clinical standpoint, it may be useful to establish
whether or not CCBs provide a greater protection from
stroke when compared with alternative antihypertensive
treatments, regardless of their type. The present overview
addressed this research question.
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We selected studies that met all of the following prespeci-
fied criteria: 1) publication in peer-reviewed journals in-
dexed in Medline; 2) inclusion of patients with clinical
diagnosis of essential hypertension; 3) occurrence of
stroke, as a prespecified end point, during follow-up; 4)
definition of stroke events in single studies; 5) assessment
of BP at baseline and follow-up visits; 6) randomized
controlled comparison of regimens based on CCBs with
regimens not based on CCBs; 7) follow-up of at least 2
years; and 8) sample size of 100 subjects or more.
Studies were identified through Medline using research
Methodology Filters10 with a publication date before Decem-
ber 15, 2003. The final search identified 13 studies11–23 that
fulfilled inclusion criteria (see Appendix for trial names). We
accepted the definition of stroke events as reported in the
individual reports. All outcome results were reported on the
basis of an intention-to-treat approach.
The reference group comprised patients randomly as-
signed to other antihypertensive drugs including diuretics,
-blockers, and ACEIs. No head-to-head comparison be-
tween CCBs and angiotensin II receptor blockers was
available from the literature. The odds ratio (OR) and 95%
confidence interval (CI) for stroke were calculated sepa-
rately for each of the 13 trials. Pooled ORs were logarith-
mically transformed, weighted for the inverse of variance,
and computed according to fixed-effect (FE) and random-
effect (RE) models. The assumption of homogeneity be-
tween individual studies was also tested. We also used a
random-effect meta-regression analysis to investigate the
baseline-corrected differences in systolic BP (follow-up
minus baseline) between the CCBs group and the refer-
ence group as potential effect modifier. All P values are for
two-sided tests. Analyses were done using the Stata 7.0
Table 1. Characteristics of trials included in the m
ABCD ALLHAT AL
Year 1998 2002 20
Age (y) 57 67
Treatment
CCB Nisoldipine Amlodipine Aml
Reference
drugs
ACE-I Diuretics A
Number of patients
CCB 235 9048 90
Others 235 15255 90
Number of strokes
CCB 11 377 3
Others 7 675 4
SBP (mm Hg) 0 1.1
Follow-up (y) 5.0 4.9
ACE-I  angiotensin-converting enzyme inhibitor; CCB  calcium ch
pressure between CCB and reference treatment.package (StataCorp LP, College Station, TX).Results
Table 1 shows the main characteristics of the clinical trials
considered. The FACET22 study enrolled patients with
hypertension and type 2 diabetes and the ABCD23 study
enrolled patients with type 2 diabetes with or without
hypertension. For the purpose of the present analysis, we
excluded the normotensive cohort of the ABCD trial,
although their BP values at entry could be compatible with
antihypertensive treatment according to current guide-
lines.24,25 Overall, there were 4040 incident cases of
stroke, 1789 among 43,053 subjects randomized to CCBs
and 2251 among the 60,740 subjects randomized to other
antihypertensive drugs.
Considering the 13 trials, a pooled reduction in the risk
of stroke was associated with use of CCBs (OR 0.90, 95%
CI 0.84–0.96; P .002 for both fixed and random effects)
(Fig. 1) with no significant heterogeneity across the studies
(2  14.00; df  14; P  .50). Because of its large
sample size, the ALLHAT study exerted a major effect on
pooled estimates.
We also performed subgroup analyses of the trials with
dihydropyridine CCBs (11 trials) and non-dihydropyridine
CCBs (4 trials). In the first analysis, there were 3048 incident
cases of stroke, 1316 among the subjects randomized to
CCBs and 1732 among the subjects randomized to other
antihypertensive drugs. The risk of stroke differed between
subjects allocated to CCBs and subjects allocated to other
drugs (FE and RE: OR 0.90, 95% CI 0.84–0.97, P  .006;
test of heterogeneity: 2  9.32, P  .502) (Fig. 1). In the
analysis of trials with non-dihydropyridine CCBs, there were
992 incident cases of stroke, 473 among the subjects ran-
domized to CCBs and 519 among the subjects randomized to
other antihypertensive drugs. The risk of stroke did not differ
between subjects allocated to CCBs and subjects allocated to
analysis
T CONVINCE ELSA FACET INSIGHT
2002 2002 1998 2000
66 56 63 65
ine Verapamil Lacidipine Amlodipine Nifedipine
-
Blockers
Diuretics
-
Blockers
ACE-I Diuretics
8179 1177 191 3157
8297 1157 189 3164
133 9 10 67
118 14 4 74
0.1 0.6 6 0
3.0 3.8 2.5 3.5
l blockers;  SBP  baseline-corrected differences in systolic bloodeta-
LHA
02
67
odip
CE-I
48
54
77
57
1.4
4.9
annedifferent drugs (FE: OR 0.92, 95% CI 0.81–1.04, P  .184;
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neity: 2  4.63, P  .201) (Fig. 1).
To assess the potential association between the reduction
in the risk of stroke and the degree of BP lowering, we
undertook a random-effect meta-regression analysis of the
log OR of stroke on the baseline-corrected differences in
achieved systolic BP between the CCB group and the
non-CCB group in single trials. Separate analyses assum-
Table 1. Continued
INVEST MIDAS NICS NORDIL
2003 1996 1999 2000
66 59 70 60
Verapamil Isradipine Nicardipine Diltiazem
-Blockers Diuretics Diuretics -Blocker
Diuretics
11267 442 204 5410
11309 441 210 5471
176 6 8 159
201 3 8 196
2 3.5 0.7 3.1
5.0 3.0 4.2 4.5
FIG. 1. Stroke events associated with calcium channel blockers (
squares represent the odds ratio in individual trials and have a size
intervals (CI) for individual trials are denoted by lines. Open dia
weighting). ACE-I  angiotensin-converting enzyme inhibitors; trial acroing a linear or quadratic relationship between the differences
in achieved systolic BP and the log ORs were also per-
formed.
As shown in Fig. 2, there was no relationship between
the log ORs of stroke and the changes in systolic BP.
Regression models different from the linear failed to
achieve significance (all P  .05). The estimated variation
in the log OR per unit increase in the difference in
SHELL STOP-2 STOP-2 VHAS
2003 1999 1999 1997
72 76 76 53
Lacidipine Felodipine
Isradipine
Felodipine
Isardipine
Verapam
Diuretics -Blockers
Diuretics
ACE-I Diuretics
942 2196 2196 707
940 2213 2205 707
37 207 207 5
38 237 215 4
1.1 0.3 0.3 1
3.6 5.0 5.0 2.0
) and other drugs in patients with essential hypertension. Black
ortional to the number of events in each study. The 95% confidence
ds represent pooled odds ratio estimates (using inverse-variancesCCBs
prop
monnyms and references are given in the Appendix.
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mental groups was only 0.014%.
Discussion
Our analysis of 13 major hypertension trials including
more than 103,000 subjects and 4040 incident cases of
stroke suggests that CCBs reduce the risk of stroke more
effectively than other classes of antihypertensive drugs and
that such an effect might be independent of the degree of
BP lowering. Overall, the relative risk reduction conferred
by CCBs amounted to 10% (95% CI 4–16%). Such benefit
applied to the nine trials with dihydropyridine CCBs (OR
0.90, 95% CI 0.84–0.97; P  .006), whereas a nonsig-
nificant 8% risk reduction was noted in the analysis of the
four trials that tested non-dihydropyridine CCBs. Because
the pooled effect sizes were similar, we preserve the pos-
sibility that the sample size for the latter analysis may have
been too small to attain significance. Alternatively, non-
dihydropyridine CCBs might be less effective than dihy-
dropyridine CCBs in reducing the risk of stroke. Results
obtained with the non-dihydropyridine CCBs were influ-
enced by the findings of the CONVINCE study, which was
stopped prematurely for nonmedical reasons and therefore
was unable to satisfy the prespecified equivalence thresh-
olds.13 In the CONVINCE study there was a nonsignifi-
cant trend toward a higher stroke rate in the verapamil
group. Of note, selectivity for vascular tissues seems to be
lesser with verapamil compared with dihydropyridine and
diltiazem.26
Comparison With Other Meta-Analyses
Our findings complete those of the second cycle of anal-
yses by the BPLTTC group8 with various aspects. First,
FIG. 2. Log odds ratio (OR) of stroke in 13 trials of calcium channel
blockers (CCB) versus other drugs in relation to the different
baseline-adjusted reduction in systolic blood pressure. The area of
each circle is inversely proportional to the variance of the log odds
ratio estimate. ACE  angiotensin-converting enzyme inhibitors;
Conv  conventional therapy; SBP  systolic blood pressure; trial
acronyms and references are given in the Appendix.our analysis did not provide separate comparisons betweenCCBs and either ACEIs or diuretics/-blockers, but an
overall comparison between CCBs and non-CCB agents.
On the other hand, diuretics, -blockers, and ACEIs are
frequently combined and the value of these regimens for
prevention of stroke as compared with regimens based on
CCBs remains uncertain. Second, we added three studies
(INVEST,11 FACET,22 and MIDAS16) whose designs
were consistent with the hypothesis tested in our analysis
and that met our inclusion criteria. Third, we excluded two
studies included by the BPLTTC group because they did
not meet our prespecified criteria, being carried out in
purely normotensive subjects27 or not found in the Med-
line database.28 Fourth, we included separate analyses of
dihydropyridine and non-dihydropyridine CCBs. Overall,
the BPLTTC analysis did not preclude the possibility of a
real, although moderate, effect of CCBs on the risk of
stroke.8 A recent overview7 compared old (diuretics/-
blockers) and new (ACEIs, CCBs) antihypertensive drugs.
This meta-analysis specifically compared CCBs with dif-
ferent drug classes on the prevention of stroke. Overall,
our design resembles that of an overview by Pahor et al9
who compared the effects of CCBs with drugs different
from CCBs. In that analysis, which included 27,743 sub-
jects, CCBs decreased the risk of stroke by 10%, as noted
in our study, but the pooled estimate was not significant (P
 .10) and the possibility of a chance effect could not be
excluded. It is conceivable that our study, with its consid-
erably larger sample size, may have had more power to
detect a real difference between CCBs and non-CCBs.
Basic Mechanisms
The basic mechanisms of the protective effect of CCBs on
stroke remain elusive. Experimental studies suggest a spe-
cific role of intracellular calcium in triggering ischemic
cell death.29–31 Specifically, an excessive calcium influx
into depolarized neurons may contribute to the necrosis of
neurons in ischemic brain area.29–31 Novel neuronal cal-
cium channel blockers, such as SB 201823-A, by blocking
central neuronal calcium influx in vitro, reduces the isch-
emic injury in two rodent models of focal stroke.32 One
might speculate that CCBs currently used for antihyper-
tensive treatment may provide some degree of neuropro-
tection by working through a similar mechanism. Further
experimental studies are needed to evaluate whether these
drugs can limit the neurologic dysfunction that follows
experimental focal stroke. Moreover, randomized clinical
trials should address the question of whether CCBs are
able to interfere with preclinical neuronal dysfunction in
patients at increased risk of stroke or Alzheimer’s dis-
ease.33 At variance with this line of thinking, administra-
tion of nimodipine, a dihydropyridine CCB, within 6 h of
acute stroke was not superior to placebo on a composite
outcome of death, dependency, and neurologic status.34
The possibility that CCBs may prevent progression of
carotid atherosclerosis is supported by the results of the
European Lacidipine Study on Atherosclerosis, which
821AJH–September 2004–VOL. 17, NO. 9 CALCIUM CHANNEL BLOCKERS IN HYPERTENSIONshowed a greater efficacy of lacidipine compared to ateno-
lol on carotid intima–media thickness progression and
number of plaques per patient, despite a smaller ambula-
tory BP reduction.14
Role of BP Reduction
The reduction in BP is the main determinant in the pre-
vention of stroke by antihypertensive drugs.6,7 The second
cycle of analyses by the BPLTTC group confirmed that the
greater the difference in follow-up BP between the ran-
domized groups, the higher the difference in the risk of
stroke.8 In the present study we investigated whether this
concept applies to regimens based on CCBs compared to
regimens based on drugs different from CCBs. Thus, we
undertook a meta-regression analysis of trials included in
the present overview to establish to what extent the BP
lowering impacted on nonpooled estimates. As shown in
Fig. 2, the protection from stroke conferred by CCBs
appeared to be independent of the degree of systolic BP
reduction. It is important to remark that all of these studies
included comparisons between active drugs, in the absence
of placebo treatment groups. Therefore, our meta-regression
analysis was specifically designed to assess the relation
between BP changes and the risk of stroke among active
treatment groups, with smaller BP changes than expected
if placebo-controlled studies would have been included.
Study Limitations
In most trials, a substantial proportion of patients did not
continue the assigned monotherapy until the end of the
study. Addition of other drugs, withdrawals of treatment,
and other reasons of nonadherence to protocol may have
led to an underestimation of the real differences in stroke
risk between randomized groups. Furthermore, we relied
on the definition and validation of stroke events reported
in single studies. Although stroke was not the unique
primary end point in these studies and adjudication of
strokes was masked in the open trials, over- or under-
reporting of events cannot be ruled out. Tabular data from
the examined studies did not allow differentiation between
the various types of stroke, particularly between the hem-
orrhagic and nonhemorrhagic ones. Another limitation
was that the relation between BP reduction and the risk of
stroke, addressed in the meta-regression analysis, may
have been affected by confounding factors.
Conclusions
The results of our overview of 13 hypertension trials, more
than 103,000 subjects and 4040 incident cases of stroke,
suggest that CCBs are slightly more effective than other
classes of antihypertensive drugs in the prevention of
stroke in patients with essential hypertension. Of particular
note, such an effect seemed unrelated to the small differ-
ences in systolic BP between randomized groups. On the
basis of these findings, CCBs should be considered inhypertensive subjects at increased risk for stroke on the
basis of individual risk factors.35,36
Appendix
Trial Acronyms
ABCD  Appropriate Blood Pressure Control in Dia-
betes trial23
ALLHAT  Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial12
CONVINCE  Controlled ONset Verapamil INvesti-
gation of Cardiovascular Endpoints trial13
ELSA  European Lacidipine Study on Atherosclero-
sis14
FACET  Fosinopril versus Amlodipine Cardiovascu-
lar Events Randomized Trial22
INSIGHT  International Nifedipine GITS Study—
Intervention as a Goal for Hypertension Treatment15
INVEST  INternational VErapamil SR/trandolapril
Study11
MIDAS  Multicenter Isradipine Diuretic Atheroscle-
rosis Study16
NICS  National Intervention Cooperative Study in
Elderly Hypertensives Study Group17
NORDIL  NOrdic DILtiazem study18
SHELL  Systolic Hypertension in the Elderly Long-
term Lacidipine trial19
STOP2  Swedish Trial in Old Patients with hyper-
tension-220
VHAS  Verapamil in Hypertension and Atheroscle-
rosis Study21
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